Latest Careteq (ASX:CTQ) News

Healthcare stocks split into two camps this week. Buyers chased clear commercial wins, while several halted names gave back early excitement once trading resumed. The biggest moves came from a collapse in Opthea, a surge in Control Bionics, and a strong jump in Biome Australia after a margin-boosting manufacturing deal.

Careteq Limited’s strategic investor Antanas Guoga has converted all his convertible notes into shares, wiping out the company’s convertible debt and simplifying its capital structure ahead of its AI healthtech growth push.

Big capital raisings, fresh trial data and a few boardroom shocks shaped healthcare trading this week. The biggest moves came from companies either fixing the balance sheet, explaining heavy selling, or pushing key drugs and devices closer to market.

Careteq Limited has cleared $125,000 in director and company secretary loans a month ahead of schedule, using proceeds from a recent $2.2 million capital raising. This move strengthens the healthtech firm’s balance sheet and removes related-party debt ahead of maturity.

Small-cap healthcare names produced the biggest share-price swings this week, while larger names advanced on sales growth, trial progress and fresh contracts. Investors rewarded companies that showed clear commercial traction, but fundraising and weak follow-through punished others.

Careteq Limited has finalised the sale of its Embedded Health Solutions subsidiary for approximately $5 million, repaid related vendor loans, and plans to concentrate on growing its HMR Referrals platform amid ongoing regulatory and compliance considerations.

A brutal clinical trial stop wiped out Immutep, while Adherium surged on faster Remote Patient Monitoring growth. Across the rest of healthcare, investors paid up for proof: accredited tests, enrolled Phase III studies, and signed multi-year contracts.

Careteq Limited has successfully raised $2.2 million through a two-tranche share placement, with a significant portion subject to upcoming shareholder approval. The funds aim to support project acquisitions, debt reduction, and working capital needs.

Cannabis and psychedelics delivered the week’s biggest winner, while a cluster of smaller caps slid on fresh losses, leadership change, and near-term uncertainty. Investors kept paying up for FDA clearances and reimbursement wins, but punished businesses where early pops quickly disappeared.

Careteq Limited reported a widening half-year loss with revenues down 18%, announcing plans to sell its Embedded Health Solutions business to strengthen its balance sheet and focus on its HMR Referral platform.

A single diagnostics update sparked a breakout week, while a handful of biotech names sold off hard despite busy newsflow. Capital raisings, takeover steps and US market pushes kept healthcare in motion heading into mid-February milestones.

Careteq Limited has agreed to sell its Embedded Health Solutions business for $5 million, aiming to strengthen its balance sheet and focus on expanding its home medication review platform amid ongoing tax disputes.